Green Cross Medical Science Corporation (142280) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Green Cross Medical Science Corporation KRW 2,912, price KRW 3,155, upside -7.7%, quality 53 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Green Cross Medical Science Corporation for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
GC Medical Science Corporation operates as a diagnostic medical device company in the vitro diagnostic industry in South Korea and internationally. The company's products include human healthcare products for the diagnosis of diabetes, non-communicable diseases, respiratory diseases, and vector borne diseases.
Show more
GC Medical Science Corporation operates as a diagnostic medical device company in the vitro diagnostic industry in South Korea and internationally. The company's products include human healthcare products for the diagnosis of diabetes, non-communicable diseases, respiratory diseases, and vector borne diseases. It offers CERA-CHEK 1Code and CERA-CHEK 1070 for diabetes; GREENCARE A1c for HbA1c, CERA-CHEK 3 in 1 GHL for multi-diagnosis; CERA-CHEK Lactate; GREENCARE Hb and CERA-CHEK Hb Plus for haemoglobin; and GCare Lipid and GCare Lipid Printer for cholesterol. The company also offers Covid-19 and flu diagnosis equipment including GENEDIA W Covid-19 Ag, GreenCare FLU2 Influenza A&B Ag, and " GENEDIA W Covid-19 & Flu A&B Ag. Additionally, it offers dengue diagnosis equipment including GENEDIA W Dengue NS1 Ag, GENEDIA W Dengue lgM/lgG Ab, and GENEDIA W Dengue NS1 & lgM/lgG Combo. Further, the company provides vet healthcare products, such as CERA-PET blood glucose monitoring system for diabetes; and CERA-PET Multi for non-communicable diseases diagnosis. The company was formerly known as Green Cross Medical Science Corporation and changed its name to GC Medical Science Corporation in May 2026. GC Medical Science Corporation was founded in 1972 and is headquartered in Yongin-Si, South Korea.
Stock analysis
Green Cross Medical Science Corporation (142280) currently trades at 3,155 KRW, while our model-based Fair Value estimate is 2,912 KRW, implying the stock looks roughly 8.4% fairly valued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 3,220 KRW per share, and 7 of the 23 models we run sit above the 3,155 KRW price.
Bear case: the Earnings-Based group reads lowest at 1,275 KRW, and 16 of the 23 models stay below the price. Evidence for this calculation is medium.
Scenario range: 2,150 KRW (bear) to 3,785 KRW (bull), the price of 3,155 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Green Cross Medical Science Corporation reported revenue of 108B KRW in FY2025 versus 102B KRW in FY2021, a compound +1.6%/yr. Reported net income was 3.7B KRW in FY2025.
Key figures
Market cap 68.6B KRW (≈ $50.4M) · P/S ratio 0.57 · Net margin 3.4% · Return on equity 9.9% · Return on assets (EBIT) −3.1% · Operating margin 1.2% · Revenue (TTM) 105B KRW · Revenue growth (YoY) −11.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 49% below its 52-week high and 32% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −8%, 142280 screens cheaper than that median.
Fair Value models
Bear 2,150 KRWFair Value 2,912 KRWBull 3,785 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+4.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.9%
Start year 2020 (pandemic). Over 10 years: +2.0% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−12.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−12.0%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.4% → 3%
⚠ Revenue per share shrinking 7.0%/yr over ~7Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+17.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +15.5% a year for the price.
Compare Green Cross Medical Science Corporation with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 628 stocks
Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score53 · Below median
Fair Value upside−8% · Above median
Profitability
Return on equity (TTM)10% · Above median
Return on assets2% · Below median
Net margin (TTM)4% · Below median
Operating margin (TTM)1% · Below median
Growth and dividend
Revenue growth−11% · Bottom 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Green Cross Medical Science Corporation Fair Value". https://www.fairvalue-calculator.com/stock/142280
Frequently asked questions
Is Green Cross Medical Science Corporation (142280) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 2,912 KRW versus a price of 3,155 KRW, about −8% upside (fairly valued).
What is the fair value of 142280?
Our model-based fair value for Green Cross Medical Science Corporation is 2,912 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 3,155 KRW.
What is the quality score of 142280?
Green Cross Medical Science Corporation has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Green Cross Medical Science Corporation (142280)?
Our model-based price target is the fair value of 2,912 KRW (as of Sep 24, 2026) from 23 valuation models. Cautious scenario 2,150 KRW, optimistic scenario 3,785 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Green Cross Medical Science Corporation stock forecast for 2026?
Our models put fair value at 2,912 KRW, about −8% upside versus a price of 3,155 KRW (fairly valued). Cautious scenario 2,150 KRW, optimistic scenario 3,785 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Green Cross Medical Science Corporation (142280)?
Green Cross Medical Science Corporation reported trailing-twelve-month revenue of about 105B KRW (latest available figure, as of Sep 24, 2026).
What growth is priced into Green Cross Medical Science Corporation (142280)?
For today's price to be fair in a discounted-cash-flow model, Green Cross Medical Science Corporation would have to grow free cash flow by +17.9 % per year for five years (discount rate 9.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -0.9 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 142280 use?
Our models discount Green Cross Medical Science Corporation at 9.1 %: a base by market capitalisation (nano), damped by beta 0.61, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Green Cross Medical Science Corporation that is +17.9 % per year a year over ten years, using the same discount rate (9.1 %) and the same formula as our fair value.
How much growth has Green Cross Medical Science Corporation (142280) delivered so far?
Over the past 5 years revenue at Green Cross Medical Science Corporation grew -0.9 % a year. The price currently implies +17.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Green Cross Medical Science Corporation (142280) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Green Cross Medical Science Corporation (+17.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Green Cross Medical Science Corporation (142280)?
The free-cash-flow yield on the price is 3.35 %: that much free cash flow Green Cross Medical Science Corporation produces per unit of market value. When it exceeds the discount rate of our models (9.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Green Cross Medical Science Corporation (142280)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Green Cross Medical Science Corporation it is 2,912 KRW per share (as of Sep 24, 2026), against a price of 3,155 KRW. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is Green Cross Medical Science Corporation stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 142280 trades above its calculated fair value: price 3,155 KRW, fair value 2,912 KRW, a gap of about −8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 142280?
No. The price is what the market pays today (3,155 KRW); the fair value is what the company's own numbers justify (2,912 KRW). For Green Cross Medical Science Corporation the two are 243.46 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Green Cross Medical Science Corporation worth?
The market values Green Cross Medical Science Corporation at about 68.6B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 3,155 KRW; our models calculate a fair value of 2,912 KRW per share.
What do the bullish and bearish scenarios say about 142280?
Our models span a range for Green Cross Medical Science Corporation: cautious scenario 2,150 KRW, base 2,912 KRW, optimistic 3,785 KRW per share (as of Sep 24, 2026, price 3,155 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Green Cross Medical Science Corporation (142280)?
Balance-sheet figures for Green Cross Medical Science Corporation (as of Sep 24, 2026): return on equity 9.9%. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is 142280 from its 52-week high?
Green Cross Medical Science Corporation trades at 3,155 KRW, about 49% below its 52-week high of 6,230 KRW and 32% above the low of 2,395 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 2,912 KRW is for.
Which stocks are comparable to Green Cross Medical Science Corporation?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Green Cross Medical Science Corporation stock attractive at the current price?
The data as of Sep 24, 2026: price 3,155 KRW, calculated fair value 2,912 KRW (−8%), Quality Score 53/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 142280 calculated?
We run Green Cross Medical Science Corporation through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 2,912 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Green Cross Medical Science Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Green Cross Medical Science Corporation (142280)?
The closing price on Sep 23, 2026 was 3,155 KRW. Our model-based fair value is 2,912 KRW, about −8% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Green Cross Medical Science Corporation right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Green Cross Medical Science Corporation
How large is the market capitalisation of Green Cross Medical Science Corporation (142280)?
The market capitalisation of Green Cross Medical Science Corporation is 68.6B KRW (≈ $50.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Green Cross Medical Science Corporation (142280)?
The price-to-sales ratio of Green Cross Medical Science Corporation is 0.57 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Green Cross Medical Science Corporation (142280)?
The net margin of Green Cross Medical Science Corporation is 3.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Green Cross Medical Science Corporation (142280)?
The return on equity (ROE) of Green Cross Medical Science Corporation is 9.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Green Cross Medical Science Corporation (142280)?
On an EBIT basis the return on assets of Green Cross Medical Science Corporation is −3.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Green Cross Medical Science Corporation (142280)?
The operating margin of Green Cross Medical Science Corporation is 1.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Green Cross Medical Science Corporation (142280)?
Revenue at Green Cross Medical Science Corporation is growing −11.1% versus a year earlier (3y avg −1.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Green Cross Medical Science Corporation (142280)?
Earnings per share at Green Cross Medical Science Corporation are growing +41.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Green Cross Medical Science Corporation (142280) carry?
The net debt of Green Cross Medical Science Corporation is 10.2B KRW (fiscal year 2025, ≈ 4.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Green Cross Medical Science Corporation in the live analysis
One click puts Green Cross Medical Science Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
